114 related articles for article (PubMed ID: 20691957)
1. Inverse agonism at serotonin and cannabinoid receptors.
Aloyo VJ; Berg KA; Clarke WP; Spampinato U; Harvey JA
Prog Mol Biol Transl Sci; 2010; 91():1-40. PubMed ID: 20691957
[TBL] [Abstract][Full Text] [Related]
2. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
[TBL] [Abstract][Full Text] [Related]
3. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
[TBL] [Abstract][Full Text] [Related]
4. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
Kenakin T
Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
[TBL] [Abstract][Full Text] [Related]
5. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
Herrick-Davis K; Grinde E; Teitler M
J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
[TBL] [Abstract][Full Text] [Related]
6. Measurement of inverse agonism of the cannabinoid receptors.
Fong TM
Methods Enzymol; 2010; 485():139-45. PubMed ID: 21050915
[TBL] [Abstract][Full Text] [Related]
7. Targeting 5-HT receptors for the treatment of obesity.
Sargent BJ; Henderson AJ
Curr Opin Pharmacol; 2011 Feb; 11(1):52-8. PubMed ID: 21330209
[TBL] [Abstract][Full Text] [Related]
8. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
9. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Prog Brain Res; 2008; 172():287-305. PubMed ID: 18772038
[TBL] [Abstract][Full Text] [Related]
10. Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.
Seimandi M; Bockaert J; Marin P
Methods Enzymol; 2010; 485():61-79. PubMed ID: 21050911
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptors: where they are and what they do.
Mackie K
J Neuroendocrinol; 2008 May; 20 Suppl 1():10-4. PubMed ID: 18426493
[TBL] [Abstract][Full Text] [Related]
12. The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.
Krobert KA; Levy FO
Br J Pharmacol; 2002 Mar; 135(6):1563-71. PubMed ID: 11906971
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists.
Wieland K; Bongers G; Yamamoto Y; Hashimoto T; Yamatodani A; Menge WM; Timmerman H; Lovenberg TW; Leurs R
J Pharmacol Exp Ther; 2001 Dec; 299(3):908-14. PubMed ID: 11714875
[TBL] [Abstract][Full Text] [Related]
14. Agonism and inverse agonism at dopamine D2-like receptors.
Strange PG
Clin Exp Pharmacol Physiol Suppl; 1999 Apr; 26():S3-9. PubMed ID: 10386247
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
Chambers JJ; Parrish JC; Jensen NH; Kurrasch-Orbaugh DM; Marona-Lewicka D; Nichols DE
J Med Chem; 2003 Jul; 46(16):3526-35. PubMed ID: 12877591
[TBL] [Abstract][Full Text] [Related]
16. Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells.
Labrecque J; Fargin A; Bouvier M; Chidiac P; Dennis M
Mol Pharmacol; 1995 Jul; 48(1):150-9. PubMed ID: 7623769
[TBL] [Abstract][Full Text] [Related]
17. Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization.
Westphal RS; Backstrom JR; Sanders-Bush E
Mol Pharmacol; 1995 Aug; 48(2):200-5. PubMed ID: 7651352
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
[TBL] [Abstract][Full Text] [Related]
19. Novel actions of inverse agonists on 5-HT2C receptor systems.
Berg KA; Stout BD; Cropper JD; Maayani S; Clarke WP
Mol Pharmacol; 1999 May; 55(5):863-72. PubMed ID: 10220565
[TBL] [Abstract][Full Text] [Related]
20. Failure to detect in vivo inverse agonism of the 5-HT(1B) receptor antagonist SB-224289 in 5-HT-depleted guinea-pigs.
Stenfors C; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):462-7. PubMed ID: 12070760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
